Abstract: The invention relates to the use of Factor H for the manufacture of a medicament to treat both chronic nephropathies which are not causally associated with proteinuria and chronic nephropathies which are causally associated with proteinuria. The invention also relates to large scale purification methods for Factor H.

Abstract: The invention relates to the use of Factor H for the manufacture of a medicament to treat both chronic nephropathies which are not causally associated with proteinuria and chronic nephropathies which are causally associated with proteinuria. The invention also relates to large scale purification methods for Factor H.

Abstract: The invention is directed to novel uses of Factor H, in particular in antibody-independent chronic nephropathies, e.g. in tubulointerstitial fibrosis (TIF). The invention is further directed to novel large scale manufacturing processes for Factor H.

Abstract: The use of a tissue glue comprising a stabilized fibrinogen preparation, which can be stored in the liquid or frozen state and comprises a chaotropic substance, and a thrombin preparation, for reducing or preventing tissue adhesions, is described.

Abstract: The C1 esterase inhibitor (C1-INH) from human plasma is a sialic-acid-containing glycoprotein which can bind other glycoproteins and glycolipids which may be components or even membrane components of microoganisms of viral and bacterial origin. In accordance with the invention, this binding can inhibit the penetration of certain viruses into target cells.

Abstract: A pharmaceutical preparation is described while is useful for the treatment of inflammatory processes being accompanied by an increased distribution of cytokines and/or tissue factor in the human body, which preparation contains Antithrombin III as active ingredient.

Abstract: The use of a tissue glue comprising a stabilized fibrinogen preparation, which can be stored in the liquid or frozen state and comprises a chaotropic substance, and a thrombin preparation, for reducing or preventing tissue adhesions, is described.

Abstract: Pharmaceutical preparation for the treatment of inflammatory processes A pharmaceutical preparation is described while is useful for the treatment of inflammatory processes being accompanied by an increased distribution of cytokines and/or tissue factor in the human body, which preparation contains Antithrombin III as active ingredient.

Abstract: A tissue adhesive is described, which contains three separate components, i.e., a stabilized, essentially fibrinogen-free protein preparation that is of storage-quality in liquid state and contains the blood coagulation factor XIII a stabilized protein preparation that is of storage-quality in liquid state and contains fibrinogen. A chaotropic substance of less than 0.28 mol/liter was added to said protein preparation to avoid or reduce the aggregation of fibrinogen, and a preparation containing thrombin, which are provided in one packaging unit prepared to be used together. Furthermore, stabilized, frozen or lyophilized protein preparations containing fibrinogen and Factor XIII are described. Said protein preparations contain fibrinogen- and Factor XIII which remains stable for more than four weeks after defrosting or reconstitution, as well as one or more added chaotropic substances in a quantity of less than 0.

Abstract: A pharmaceutical preparation is described while is useful for the treatment of inflammatory processes being accompanied by an increased distribution of cytokines and/or tissue factor in the human body, which preparation contains Antithrombin III as active ingredient.